Participants in the study will be randomly assigned to receive either Upadacitinib or a placebo, which is a substance with no active medication. The study is designed to be double-blind, meaning neither the participants nor the researchers will know who is receiving the actual medication or the placebo. This helps ensure that the results are not influenced by expectations. The study will last for a period of time, during which participants will take the medication orally in the form of a modified-release tablet. The goal is to observe any changes in the severity of eczema symptoms and overall skin condition over the course of the study.

Throughout the study, participants will be monitored for any improvements in their eczema symptoms, such as reduced itching and inflammation, as well as any potential side effects. The study aims to provide valuable information on whether Upadacitinib can be an effective treatment option for those suffering from moderate to severe eczema. By participating in this study, researchers hope to gain insights that could lead to better management and treatment options for individuals with this challenging skin condition.

In this early‑stage trial, volunteers are randomly placed into one of the two groups, and the staff who evaluate the results do not know which treatment each person received (blind assessment). Over several weeks, participants come to the clinic for visits where the ointment is applied, basic checks such as pulse and blood pressure are taken, and simple lab tests are performed to look for any side effects. The wound area is inspected regularly for irritation, and overall health is monitored throughout the study period.

People in the study are assigned by chance to receive different doses of JNJ-95597528 or placebo, and neither the participants nor the study team know which treatment is given during the study. Treatment is given over a period of time, and the skin condition is followed during the study visits. The study is designed to learn whether this medicine may help reduce the signs and symptoms of Atopic Dermatitis.

The study is designed as a split-body study, which means that different treatments will be applied to different areas of the body on the same person. Before starting the maintenance treatment with the creams, patients will first receive treatment with a corticosteroid cream, which is a medication that reduces inflammation, for about four weeks to clear the skin lesions. Corticosteroids are commonly used to treat skin inflammation and help calm down active eczema flare-ups. Once the skin has cleared, the maintenance phase begins, where one moisturizing cream will be applied to one study area on the body, another cream or no treatment will be applied to another area, and this will continue for up to 90 days or until the eczema comes back.

During the study, the time it takes for the eczema to return on each treated area will be measured, which is the main focus of the research. Other aspects that will be looked at include how itching changes over time in the different areas and whether any unwanted effects occur during the treatment period. Patients will report when they notice their eczema returning and how much itching they experience using a rating scale.

The purpose of this research is to determine how well ruxolitinib cream works in treating moderate atopic dermatitis in young patients. During the study, participants will apply either ruxolitinib cream or the vehicle cream to affected areas of their skin, excluding the scalp. The treatment period lasts for 8 weeks, followed by an extended observation period.

The study will monitor changes in skin condition, including improvements in rash coverage, intensity of itching, and overall disease severity. Blood samples will be collected from some participants to measure how much of the medication enters the bloodstream. The research will also track any side effects that may occur during the treatment period.

Participants receive study treatment over a long period of time and are followed during the study to see how they do. Some participants may receive lebrikizumab, while others may receive the placebo to match LY3650150. The study is designed to gather information over time about how safe the treatment is and how well it works for this skin condition.

The study will assess improvement in atopic dermatitis using several measurements, including the Validated Investigator’s Global Assessment for Atopic Dermatitis (a scoring system used by doctors to rate the severity of eczema) and the Eczema Area and Severity Index (a tool that measures the extent and severity of eczema). The research will also track changes in pruritus (itching) and skin pain using numerical rating scales where patients rate their symptoms.

During the 24-week study period, participants will receive either rocatinlimab or placebo treatment. The study is double-blind, meaning neither the participants nor the researchers will know who is receiving the actual medication versus the placebo until the study is complete. This approach helps ensure that the results aren’t influenced by expectations about the treatment.

The purpose of the study is to evaluate how well amlitelimab works in reducing the symptoms of atopic dermatitis and to assess its safety. Participants will receive the treatment over a period of 24 weeks. During this time, they will have regular check-ups to monitor their skin condition and overall health. The study aims to see if amlitelimab can help clear the skin or significantly reduce the severity of the symptoms compared to those who receive a placebo.

In addition to amlitelimab, the study will also involve the use of other topical treatments like tacrolimus and pimecrolimus, which are applied directly to the skin. These treatments are commonly used to manage atopic dermatitis by reducing inflammation and itching. The study will help determine the best approach to treating moderate-to-severe atopic dermatitis and provide valuable information on the potential benefits of amlitelimab for patients with this condition.

The purpose of the study is to evaluate how well Lebrikizumab works in reducing the severity of atopic dermatitis symptoms in both adults and adolescents. Participants will receive the treatment over a period of 24 weeks. During this time, they will have regular visits to monitor their condition and any changes in their symptoms. Some participants may receive a placebo, which is a substance with no active medication, to compare the effects of the treatment.

The study aims to see if Lebrikizumab can help improve the skin condition and overall quality of life for those with moderate-to-severe atopic dermatitis. Participants will be assessed on various aspects, such as the extent of skin improvement and relief from itching. The study will also look at how the treatment affects sleep and daily activities, providing a comprehensive view of its impact on the participants’ lives.

The purpose of the study is to evaluate how effective and safe Lebrikizumab is for people with moderate-to-severe Atopic Dermatitis. Participants in the study will receive the treatment over a period of 24 weeks. During this time, researchers will monitor changes in the severity of the disease, as well as any signs and symptoms experienced by the participants.

Throughout the study, participants will have regular visits to assess their progress and any improvements in their condition. The study aims to gather information on how well Lebrikizumab works in reducing the symptoms of Atopic Dermatitis and improving the quality of life for those affected by this condition.

The purpose of the study is to assess the safety and effectiveness of BP1.7881 in adults with moderate-to-severe atopic dermatitis. Participants in the trial will be randomly assigned to receive either the BP1.7881 tablet or a matching placebo tablet, which looks like the real medication but does not contain the active ingredient. The study will last for 12 weeks, during which participants will take the tablets and attend regular check-ups to monitor their condition and any changes in their symptoms.

Throughout the trial, researchers will be looking at various outcomes, such as changes in the severity of the skin condition and the level of itching experienced by participants. The goal is to determine whether BP1.7881 can provide significant relief from the symptoms of atopic dermatitis compared to the placebo. This study is important for understanding how well BP1.7881 works and ensuring it is safe for people with this skin condition.

The purpose of the study is to evaluate the effectiveness and safety of Upadacitinib, which is a type of medication known as a Janus Kinase (Jak) 1 Inhibitor. This medication is taken orally in the form of a modified-release tablet, which means it is designed to release the active ingredient slowly over time. Participants in the study will receive either Upadacitinib or a placebo, which is a substance with no active medication, to compare the outcomes.

Throughout the study, participants will be monitored to see how their eczema symptoms change over time. The study will last for several months, and participants will have regular check-ups to assess their skin condition and overall health. The goal is to determine if Upadacitinib can significantly improve the symptoms of eczema and enhance the quality of life for those affected by this condition.

During the study, participants will receive lebrikizumab treatment over a period of time, with the study lasting up to 24 weeks. The medication will be given at a dose of up to 500 milligrams per day, with a total amount of up to 3750 milligrams throughout the treatment period. The study will look at both areas of skin that show visible signs of the condition and areas that appear normal to see how the treatment affects the skin barrier, which is the protective outer layer of the skin that helps keep moisture in and harmful substances out.

The study will measure various aspects of the skin condition and how it responds to treatment. This includes looking at how much the overall severity of the skin condition improves, whether itching gets better, and how the condition affects quality of life. The study will also examine the skin in more detailed ways by measuring things like moisture levels, the natural protective substances in the skin, and other physical properties of the skin. Some measurements will involve taking samples from the skin surface using special tape, and in some adult participants, small skin samples may be taken. Blood tests will also be done to check vitamin D levels.

The purpose of this study is to evaluate the long-term safety and how well the treatment works over an extended period of time. The study will track any unwanted effects that might occur and will measure how the condition responds to the treatment. Participants will continue receiving the medication they were assigned in the previous study and will attend regular visits where doctors will examine their skin and ask questions about their symptoms and quality of life.

During the study, doctors will check for any side effects and measure how much the skin condition improves. They will look at the area of skin affected and how severe the symptoms are, as well as how much the condition impacts daily life activities. Blood samples will be taken to measure the amount of medication in the body and to check if the body develops any reaction to the treatment. The study will also track changes in general health measures to ensure the treatment remains safe over time.

The study is designed for adults between 18 and 75 years old who have had atopic dermatitis for at least one year and whose condition is moderate to severe and not well controlled by creams or ointments applied to the skin. Participants will be randomly assigned to receive either BFB759 or placebo for a treatment period of 14 weeks. During the study, participants will need to attend regular visits and avoid using certain other medications.

The main goal is to measure changes in the severity and extent of skin symptoms using a scoring system that looks at redness, thickness, scratching marks, and the area of skin affected. The study will also track how many people experience significant improvement in their symptoms, changes in the amount of body surface area affected by the condition, overall disease severity scores, and improvements in itching. The safety of the treatment will be monitored by recording any unwanted side effects that occur during the study.

The study involves two groups of participants – one receiving rocatinlimab injections under the skin along with topical treatments, and another receiving placebo injections with the same topical treatments. The treatment period lasts for 24 weeks, during which the effectiveness of the medication will be evaluated by examining improvements in skin appearance and reduction in disease severity.

Throughout the study, doctors will monitor how well the treatment works by checking if participants’ skin becomes clearer and if their symptoms, such as itching and skin pain, improve. They will pay special attention to how the treatment affects different areas of the body, including the face and hands, in people who have atopic dermatitis in these locations.

The research will assess whether rocatinlimab can improve the condition of patients’ skin by reducing the severity and affected areas of eczema. The study will measure improvements in skin appearance, reduction in pruritus (itching), decrease in skin pain, and overall quality of life for participants. It will specifically examine whether participants achieve clear or almost clear skin on their face, hands, and other body areas after treatment.

Throughout the 24-week study period, participants will receive either rocatinlimab or placebo and will need to regularly report their symptoms and complete assessments. The research is designed for adults who have had atopic dermatitis for at least 12 months and have not responded adequately to previous treatments for their condition.

The purpose is to compare how well the various doses improve skin symptoms versus placebo after approximately three months, using a scoring system called the EASI score, which measures the extent and severity of the rash.

During the trial, participants take the assigned tablet once daily for several weeks. At scheduled visits they have simple skin examinations and answer questions about itch intensity, using tools such as the vIGA rating (which classifies the skin as clear, almost clear, or worse) and the PP-NRS4 scale (a short questionnaire where higher numbers indicate more itching). Safety is monitored through checks for side effects, basic lab tests, vital signs, and heart scans (ECG). The study continues for about 12 weeks before the results are evaluated.

The study will monitor how different doses of the drug affect the skin and how the body processes the medication over a period of 16 weeks. During this time, the condition of the skin and the intensity of itching will be observed to determine how well the treatment works compared to the inactive substance.

The purpose of this study is to find out how well TRIV-509 works in improving the symptoms of moderate to severe atopic dermatitis in adults, and also to learn about its safety and how the body processes the medication. The study will look at whether the treatment can reduce the severity of the skin condition and improve symptoms such as itching. During the study, participants will receive the medication or placebo through injections under the skin for a period of 12 weeks. The total study duration will be longer as participants will be followed up to see how they respond to the treatment and to monitor for any side effects. Throughout the study, participants will be asked to continue using a moisturizer on their skin at a steady amount.

The study will measure various outcomes to understand if the treatment is working, including the percentage of people whose atopic dermatitis improves after 16 weeks. The study will also track any unwanted effects that might occur, changes in vital signs such as blood pressure and heart rate, results from heart rhythm tests, and laboratory test results from blood samples. Additionally, the study will measure how the medication moves through the body and whether the body develops any immune response against the medication. Participants will need to avoid excessive sun exposure and tanning beds during the study period.

The purpose of this study is to compare how well upadacitinib works compared to dupilumab in treating the symptoms of atopic dermatitis in people who did not have good results with dupilumab. The study will measure how much the skin condition improves and how much the itching decreases. Participants will need to have certain levels of disease activity at the start, including a specific score that measures the extent and severity of their eczema, a score that shows how much of their body is affected by the skin condition, and a score that measures how bad their itching is. They will also need to have been using dupilumab according to its approved instructions but still have symptoms that are not well controlled.

During the study, participants will receive either upadacitinib or dupilumab for a treatment period of up to 32 weeks. They will need to continue using a basic skin moisturizer twice daily throughout the study. The main measure of success will be checked at week 8 to see how many people have at least a 90 percent reduction in their eczema symptoms. The study will also look at how many people have their itching reduced to very low levels and how quickly these improvements happen. Throughout the study, the safety of the treatments will be carefully monitored.

The purpose of this study is to find out how well different doses of KT-621 work compared to placebo in treating moderate to severe atopic dermatitis. The study will also look at how safe the medication is and what side effects it may cause. Researchers want to understand if this new treatment can help reduce the symptoms of atopic dermatitis, including the extent of skin involvement, the severity of the rash, and the itching that people experience.

The study has two main parts. In the first part, which lasts 16 weeks, people are randomly assigned to receive either KT-621 at different dose levels or placebo. Neither the people in the study nor the doctors know who is receiving the actual medication or placebo during this time. After the first 16 weeks, there is a second part where everyone receives KT-621 in an open manner, meaning both the people in the study and the doctors know what is being given. This second part continues up to week 68. Throughout the study, doctors will measure changes in the skin condition, the amount of itching, and any side effects that occur.

The study will last for 16 weeks of treatment. During this time, participants will visit the study site regularly so doctors can check their skin condition and overall health. The doctors will use a scoring system to measure how clear the skin becomes during treatment. They will look for people whose skin becomes clear or almost clear with at least a 2 point improvement from when they started the study. The study will also carefully watch for any unwanted effects that might happen during treatment and after the study ends.

Participants must be adults who are 18 years of age or older. Their atopic dermatitis must be diagnosed according to specific medical criteria and must be at a moderate to severe level at both the first visit and when treatment starts. The study is designed so that neither the participants nor the doctors know who is receiving the actual medication and who is receiving placebo during the treatment period. This helps ensure the results are measured fairly and accurately.

The purpose of this research is to understand how lebrikizumab affects the skin at a molecular level and how these changes relate to improvements in skin condition over time. The study will look at how the medication works both during treatment and after treatment is stopped. The total duration of treatment for each participant is 60 weeks.

During the study, participants will receive injections of the medication and undergo skin examinations. Small samples of skin tissue will be taken to study the effects of the treatment. The study will also measure water loss from the skin to assess improvements in skin barrier function. Participants will be adults who have not previously used similar medications and have had atopic dermatitis for at least one year.

The purpose of this research is to evaluate how safe abrocitinib is when used for a long time in children with this skin condition. During the study, participants may receive the study medication either alone or together with other skin treatments that are applied directly to the skin. The medication will be given using a special measuring device (oral syringe) to ensure the correct dose is taken.

The study will last for 24 months, during which time doctors will regularly check the children’s health and how well the treatment is working. The medicine will be given as a liquid that can be taken by mouth, with a maximum daily dose of 100 mg/ml. Throughout the study, doctors will monitor any changes in the skin condition and keep track of any side effects that may occur.

The research will compare rocatinlimab against placebo in adolescents who have not responded well enough to previous treatments with topical corticosteroids. The study will last for 52 weeks, with the main evaluation of the medication’s effectiveness happening at week 24. During the study, researchers will monitor changes in the severity of skin symptoms and the intensity of itching.

Throughout the study, participants will receive either rocatinlimab or placebo through injections. The study will measure several aspects of the skin condition, including how much of the body is affected by the disease, the severity of symptoms, and improvements in itching and skin pain. This is known as a double-blind study, which means neither the participants nor the doctors conducting the study will know who is receiving the actual medication versus the placebo during the treatment period.

The purpose of this research is to determine how well ATI-045 works compared to placebo in treating atopic dermatitis symptoms. During the study, participants will receive either ATI-045 or placebo injections for a period of 24 weeks. The maximum daily dose of the medication will be 600 mg, with a total maximum dose of 4200 mg over the treatment period.

The medication being tested works by targeting a specific protein in the body called thymic stromal lymphopoietin, which plays a role in causing inflammation in atopic dermatitis. Throughout the study, doctors will monitor how well the treatment works by measuring changes in the severity and extent of skin symptoms. They will also track any side effects that may occur during the treatment period.

The purpose of this research is to evaluate how well different doses of IMG-007 work compared to placebo in treating atopic dermatitis. The study will examine if the medication can reduce the severity and extent of skin symptoms in adults with this condition. The medication will be tested over a period of 20 weeks to determine its effectiveness and safety.

During the study, participants will receive either IMG-007 or placebo through injections under the skin. The study is designed as a double-blinded trial, which means neither the participants nor the doctors conducting the study will know who receives the actual medication and who receives the placebo. Participants will be allowed to continue using regular moisturizers throughout the study period.

The study will involve participants who have already completed an earlier trial of APG777. During this extended treatment period, participants will continue receiving APG777 injections for up to three years. Some participants may receive a placebo during the study. Throughout the study, participants will be allowed to use non-medicated moisturizers to help manage their skin condition.

The research will monitor how well the medication controls atopic dermatitis symptoms over time, including improvements in skin appearance, reduction in affected areas, and relief from itching. The study will also track any side effects that may occur during the extended treatment period. Regular assessments will measure the amount of APG777 in participants’ blood to understand how the medication works in the body over a longer period.

The purpose of this research is to understand how different doses of GHZ339 work compared to placebo in treating atopic dermatitis, specifically looking at how much the skin condition improves after 16 weeks of treatment. The study is designed as a platform trial, which means it will test multiple treatments simultaneously.

During the study, participants will receive either GHZ339 injections or placebo injections, along with various topical medications that are applied directly to the skin. The treatment period will last for several months, during which participants will have regular check-ups to monitor their skin condition and overall health. The effectiveness of the treatment will be measured by examining changes in the severity and extent of skin inflammation.

The study will last for 16 weeks and follows a randomized, double-blind design where some participants will receive abrocitinib while others will receive placebo. Throughout the study, researchers will monitor how the treatment affects the severity and extent of eczema symptoms, including the intensity of itching and overall skin appearance. They will also track improvements in quality of life and sleep patterns in the participating children.

Participants in the study will continue using their regular topical medications for eczema while adding either abrocitinib or placebo. The study will also assess how children respond to the taste and experience of taking the medication, as well as monitoring for any side effects or safety concerns that might arise during treatment.

The purpose of the study is to learn more about how the body absorbs the Etrasimod Arginine mini tablets when they are mixed with different foods like applesauce, chocolate pudding, yogurt, or just water. The study will also look at how the mini tablets taste when mixed with these foods. Participants in the study will take a single dose of the mini tablets in different forms, and researchers will compare how the body absorbs the medication in each case.

The study involves healthy adult participants who will take part in a series of tests to see how the medication is absorbed and how it tastes. The study will help researchers understand the best way to deliver the medication to patients in the future. Participants will be monitored for any side effects and will provide feedback on the taste and feel of the mini tablets. This information will be used to improve the medication for future use in treating the diseases being studied.

The purpose of the study is to see if regular use of SanaCutan® Basiscreme can reduce the occurrence of atopic dermatitis in infants who have a high familial risk of the disease. The study will compare two groups of infants: one group will use the cream regularly, while the other group will not receive any treatment. The main goal is to determine if the group using the cream has a lower rate of developing atopic dermatitis by the age of 6 months compared to the group that does not use the cream.

Participants in the study will be monitored over a period of time to observe the development of atopic dermatitis and other related symptoms such as dry skin, itching, and eczema. The study will also track any adverse events or reactions to the cream. The findings will help understand the effectiveness of the cream in preventing atopic dermatitis in high-risk children.

The purpose of the study is to evaluate how well JNJ-95475939 works in reducing the symptoms of atopic dermatitis compared to a placebo. Participants in the study will be randomly assigned to receive either the new medication, Dupixent, or a placebo. The study is designed to be double-blind, meaning neither the participants nor the researchers will know who is receiving which treatment. This helps ensure that the results are unbiased. The study will take place over a period of 24 weeks, during which participants will receive regular injections and attend follow-up visits to monitor their progress and any side effects.

Throughout the study, participants will be closely monitored by healthcare professionals to ensure their safety and to assess the effectiveness of the treatments. The main goal is to see if the new medication can help improve the skin condition and provide relief from the symptoms of atopic dermatitis. This study is an important step in finding new and effective treatments for people living with this challenging skin condition.

The purpose of the study is to evaluate how effective different doses of lunsekimig are in improving skin conditions in adults with moderate to severe atopic dermatitis. Participants in the study will receive one of three different doses of lunsekimig or a placebo, administered through an injection under the skin. The study will last for several months, during which participants will have regular check-ups to monitor their skin condition and overall health.

Throughout the study, researchers will assess changes in the severity of the skin condition using a tool called the Eczema Area and Severity Index (EASI). They will also look at other factors, such as the amount of skin affected by the condition and the impact on participants’ quality of life. The study aims to provide valuable information on the potential benefits and safety of lunsekimig for treating atopic dermatitis.

Participants in the study will receive either the treatment RO7790121 or a placebo. The study will last for several weeks, during which participants will be monitored to see if there is a significant improvement in their skin condition. The main goal is to see if there is at least a 75% improvement in the severity of the eczema by the 16th week of the study.

Throughout the study, various aspects will be observed, such as changes in the skin’s condition, any side effects, and overall quality of life. The study aims to provide valuable information on whether RO7790121 can be a beneficial treatment option for those suffering from moderate to severe atopic dermatitis.

Participants in the study will receive either cyclosporine or methotrexate over a period of 32 weeks. Ciclosporin is given as an oral liquid, while methotrexate is provided as an oral solution. The study will also include a placebo group to help understand the effects of the medications better. Throughout the study, participants will have regular check-ups to monitor their progress and any side effects they might experience. The study aims to see if there is a significant improvement in the skin condition of the participants by the end of the treatment period.

In addition to the main medications, the study will also involve the use of tacrolimus and mometasone furoate ointments, which are applied topically to the skin. These ointments are used to help manage symptoms and provide additional treatment options. The study will assess various aspects of the participants’ skin condition, including the severity of eczema, the level of itching, and the overall quality of life related to their skin health. The goal is to gather comprehensive data on how these treatments can improve the lives of those affected by moderate to severe atopic dermatitis.

The study is divided into two parts. In Part A, the effectiveness of APG777 will be compared to the placebo after 16 weeks of treatment. In Part B, three different doses of APG777 will be tested against the placebo, also over a 16-week period. Throughout the study, participants will receive regular injections and attend scheduled visits to monitor their progress and any side effects. The study aims to provide valuable information on how well APG777 works and its safety profile over time.

Participants will be monitored for changes in their skin condition, including the severity and area affected by eczema, which is a common symptom of Atopic Dermatitis. The study will also track any adverse events or side effects that may occur during the treatment period. The overall duration of the study is expected to last up to 106 weeks, allowing researchers to gather comprehensive data on the long-term effects of APG777.

Participants in the study will be randomly assigned to use either the Ruxolitinib cream or a similar cream without the active ingredient, known as a placebo. The study is designed to be double-blind, meaning neither the participants nor the researchers will know who is receiving the active treatment or the placebo. This helps ensure that the results are unbiased. The study will last for several weeks, during which participants will apply the cream to their skin and attend regular check-ups to monitor their progress and any side effects.

The main goal of the study is to see if the Ruxolitinib cream can significantly improve the symptoms of atopic dermatitis, such as reducing the severity of skin inflammation and itchiness. Participants’ skin condition will be assessed at various points throughout the study to track improvements. The study will also gather information on any side effects experienced by participants to ensure the treatment is safe. This research could potentially lead to a new treatment option for those suffering from moderate atopic dermatitis.

Participants in the study will be randomly assigned to receive either one of the investigational treatments or a placebo. The study is designed to be double-blind, meaning neither the participants nor the researchers will know who is receiving which treatment. This helps ensure that the results are not biased. The study will last for several weeks, during which participants will have regular check-ups to monitor their skin condition and overall health. The main goal is to see if there is a significant improvement in the skin condition, measured by a tool called the Eczema Area and Severity Index (EASI), which assesses the extent and severity of eczema.

Throughout the study, participants will be closely monitored for any side effects or changes in their health. The researchers will also track any changes in vital signs, such as heart rate and blood pressure, as well as results from laboratory tests. The study aims to provide valuable information on whether these new treatments can offer a safe and effective option for people suffering from moderate to severe atopic dermatitis.